The group is expanding its mRNA-4359 trial to include first-line melanoma.
ApexOnco Front Page
Recent articles
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
Roche dumps another partnered asset.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
